Yes, but keep the medication in its original packaging with a copy of the prescribing information or trial protocol. Some countries may require a doctor's note or import permit for investigational drugs, so check the destination’s customs regulations in advance.
Standard workplace drug screens target substances of abuse (e.g., opioids, cannabinoids) and do not include SARMs or SERMs like enclomiphene. However, anti-doping agencies may test for performance-enhancing agents; enclomiphene could be flagged under “hormone-modulating agents.”
In trial formulations the 50 mg tablet is typically white, round, and may bear a debossed imprint such as “EN-50.” Appearance can vary between compounding pharmacies, so verify the imprint with your prescriber.
Clomiphene is a racemic mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene is the more active isomer for stimulating GnRH release, whereas zuclomiphene has a longer half-life and weaker activity.
Enclomiphene has been investigated primarily for male hypogonadism. Female fertility treatments continue to use the racemic clomiphene citrate, which has a well-established safety profile.
Clinical studies report measurable increases in serum testosterone within 2-4 weeks, with peak levels often reached at 8-12 weeks of consistent dosing.
Yes. Liver-function tests, complete blood count, and hormone panels (testosterone, LH, FSH) are recommended every 4-6 weeks initially, then at longer intervals once stable.
Concurrent use is generally discouraged because the intended purpose of enclomiphene is to stimulate endogenous testosterone production. Combining it with exogenous testosterone may blunt its effect and increase side-effect risk.
Take the missed tablet as soon as you remember, unless it is near the time of the next scheduled dose. In that case, skip the missed dose and resume the normal once-daily schedule; do not double-dose.
No MHRA-approved generic product exists in the UK market. Enclomiphene is currently only accessible through clinical-trial enrolment or specialized compounding arrangements.
Enclomiphene (chemical name Enclomiphene citrate) is a selective estrogen receptor modulator (SERM) used in experimental hormone-therapy protocols. In the United Kingdom it is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for any indication, and it is only available within clinical-trial settings or via specialty compounding pharmacies. The medication is supplied as a 50 mg oral pill.
Enclomiphene belongs to the SERM family, which means it binds to estrogen receptors but produces tissue-specific actions:
Because enclomiphene acts only on estrogen receptors in the hypothalamus and pituitary, it does not directly increase estrogen levels, which reduces the risk of estrogen-related side effects such as gynecomastia. The drug’s oral bioavailability is moderate, with peak plasma concentrations occurring roughly 4-6 hours after ingestion. It is metabolised primarily by the cytochrome P450 3A4 (CYP3A4) pathway and eliminated in the feces and urine.
Because there is no approved indication, any therapeutic use must occur under the supervision of a specialist investigator or an endocrinology clinic participating in a trial protocol.
Although not approved, several peer-reviewed studies have examined enclomiphene for male secondary hypogonadism.
Disclaimer: Off-label use of enclomiphene requires a thorough risk-benefit assessment by a qualified endocrinologist and should only be undertaken within a monitored clinical setting.
Most of these events resolve without medical intervention; dose adjustment or temporary discontinuation may be advised if symptoms persist.
General advice: Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and dietary habits to their prescribing clinician before starting enclomiphene.
Note: Dosing recommendations above reflect the most common regimen used in published research. Individual therapy must be tailored by a specialist based on biochemical response and tolerability.
This article provides educational information about enclomiphene citrate and is not a substitute for professional medical advice. Treatment decisions, including the use of investigational or off-label therapies, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
